中国临床药理学杂志2016，Vol.32Issue(13)：1175-1177,1181,4.DOI:10.13699/j.cnki.1001-6821.2016.13.007
贝伐单抗联合卡铂治疗非小细胞肺癌恶性胸腔积液的临床研究
Clinical trial of bevacizumab combined with carboplatin in the treatment of non-small cell lung cancer with malignant pleural effusion
摘要
Abstract
Objective To observe the clinical effect of bevacizumab plus carboplatin in the treatment of patients with non -small cell lung cancer ( NSCLC ) and malignant pleural effusion ( MPE ) , and observe the change of serum tumor markers .Methods A total of 46 cases of NSCLC with MPE patients were randomly divided into treatment group and control group , 23 cases in each group.Patients in two groups were treated with conventional chemotherapy , chemotherapy regimen for intra-venous infusion of pemetrexed 500 mg・ m-2 on day 1, carboplatin at an AUC 6 intravenous drip.The treatment group was given bevacizumab 5 mg・ kg -1 on the basis of conventional treatment .The control group was injected normal saline.The course was 21 d for 1 cycles, all patients treated for 6 cycles.The short-term effects, adverse reactions and chan-ges of serum tumor markers in two groups were compared .Results The total effective rate in treatment group was 86.96%, significantly higher than 65.21%in control group (P<0.05).The control rate in treatment group was significantly higher than control group ( P<0.05 ) .The inci-dence rate of adverse drug reactions in two groups had no statistical difference (P>0.05).After treatment, the hypoxia inducible factor -1α(HIF-1α), cancer embryo antigen, vas-cular endothelial growth factor (VEGF), squamous cell carcinoma antigen (SCCAg), neuron specific enzyme (NSE) of the two groups were significantly lower than before treatment , treatment group decreased more significantly (P<0.05).Conclusion Bevacizumab can significantly reduce the levels of tumor markers of NSCLC with MPE patients, reduce the pleural effusion , and improve the remission rate .关键词
贝伐单抗/卡铂/非小细胞肺癌/恶性胸腔积液/肿瘤标志物Key words
bevacizumab/carboplatin/non-small cell lung cancer/malignant pleural effusion/tumor marker分类
医药卫生引用本文复制引用
迟晶,白阳,陈虹..贝伐单抗联合卡铂治疗非小细胞肺癌恶性胸腔积液的临床研究[J].中国临床药理学杂志,2016,32(13):1175-1177,1181,4.基金项目
卫生部基金资助项目（W2013GJ65）；国家临床重点专科建设基金资助项目 （）
